Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

U.S. Registry Data Confirm Liver Risk With Controversial Vasculitis Drug

(MedPage Today) -- A new study may add fuel to the fire already burning around avacopan (Tavneos), approved in 2021 to treat anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV), which the FDA wants drugmaker Amgen to pull...

U.S. Registry Data Confirm Liver Risk With Controversial Vasculitis Drug

We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.

Read the original at medpagetoday.com →

More in Health & Medicine

More from Monday 24 August →